Status:

RECRUITING

Pediatric Percutaneous Ultrasound Gastrostomy Technique

Lead Sponsor:

CoapTech

Collaborating Sponsors:

Children's Hospital of Philadelphia

Columbia University

Conditions:

Gastrostomy

Gastrostomy Complications

Eligibility:

All Genders

Up to 21 years

Phase:

NA

Brief Summary

The purpose of this research study is to test a new device called the PUMA-G Pediatric System. The research will measure if the device works well to safely aid doctors placing gastrostomy feeding tube...

Detailed Description

This is a multi-center, non-randomized, non-blinded feasibility study to evaluate the performance and safety of the Percutaneous Ultrasound Gastrostomy (PUG) technique in the pediatric population. A ...

Eligibility Criteria

Inclusion

  • Informed consent must be obtained from the patient or a Legally Authorized Representative (ex. parent/guardian) before any study-specific assessment is performed
  • Weight ≥5 (Phase 0, Phase 1, Phase 2)
  • Weight ≥3kg and \<10kg (Phase 3)
  • Estimated abdominal wall thickness ≤3cm
  • Indication for gastrostomy tube placement, with or without jejunal access tubing via gastrostomy tract, determined to be present for any of the following reasons:
  • Anatomic: Ear, nose, or throat abnormalities (Pierre-Robin sequence cleft lip palate)
  • Neurologic: Head trauma, Cerebral palsy
  • Bowel Disease: Short Bowel syndrome, intestinal dysmotility, inflammatory bowel disease, malabsorption
  • Failure to Thrive: Cystic Fibrosis, Cholestasis, AID, Chronic renal failure, and food refusal
  • Patient determined to be an appropriate candidate for PUG, PEG, or PRG by the clinical care team
  • Anticipated discharge \> 24 hrs following gastrostomy

Exclusion

  • Temperature ≥ 38 C
  • Systolic BP \< 80 or \> 180 mmHg
  • Heart Rate \< 50 or \> 160
  • Estimated abdominal wall thickness \>3cm
  • Coagulopathy defined by INR \> 1.7 or Platelets \<50,000
  • Presence of a contraindication to being in proximity to a magnet (e.g. implantable metallic device).
  • History of prior gastrostomy, gastrectomy (partial or complete), or abdominal trauma or upper-abdominal surgery.
  • Scoliosis
  • Atypical organ placement including microgastria
  • Involvement in other investigational trials within 30 days prior to screening,
  • Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test
  • Patients with HgB \< 7g/dL, or fluid resuscitated within 48hrs prior, or received blood transfusion within 48hrs prior, or active life threatening GI bleeding
  • Esophageal Diseases: Atresia, stricture, caustic ingestion
  • Spinal anomalies or atypical organ placement
  • Any other medical condition(s) that may put the patient at risk or influence study results in the investigator's opinion, based on the performance of a pre-procedural assessment.

Key Trial Info

Start Date :

July 7 2023

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 31 2024

Estimated Enrollment :

80 Patients enrolled

Trial Details

Trial ID

NCT05966311

Start Date

July 7 2023

End Date

December 31 2024

Last Update

March 29 2024

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Children's National Hospital

Washington D.C., District of Columbia, United States, 20010

2

Nyph/Cumc

New York, New York, United States, 10019

3

Children's Hospital Of Phildelphia

Philadelphia, Pennsylvania, United States, 19104